ORYZON GENOMICS, S.A. desde 16/07/2019 hasta 16/07/2019 16/07/2019 09:05 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks ORYZON announces that data from its ETHERAL Phase IIa clinical trial of vafidemstat in Alzheimer’s patients were presented yesterday at the Alzheimer´s Association International Conference (AAIC-2019) Número de registro: 280225